Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology

On November 22, 2016 NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, reported that the Company’s abstract reviewing data on the company’s CD19.taNK program has been accepted for an oral presentation at the upcoming 58th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in San Diego, CA, December 3-6, 2016 (Press release, NantKwest, NOV 22, 2016, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2225427 [SID1234516781]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NantKwest’s transition from preclinical to clinical studies continues to make significant progress," said Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. "In these preclinical studies, aNK cells expressing a CD19-CAR (CD19.taNK) demonstrated strong killing of CD19-positive cancer cells. In addition, direct tumor injections of CD19.taNK into a fully immunocompetent mouse model induces tumor clearance and protection from tumor re-challenge, suggesting the induction of a memory (‘vaccine’) protective effect after the injection of the CD19.taNK cell."

Presentation Summary

Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge

Abstract #466, View Source
Presenter: Laurent Boissel, PhD, NantKwest, Woburn, MA
Sunday, December 4, 2016, 5:15 PM, Room 5AB
This poster will review the potential use of CD19.taNK cells to effectively kill cancer cells. In vivo preclinical studies of direct tumor injection of CD19.taNK cells induces significant tumor regression and significantly improved survival, with 75% of the mice showing complete tumor regression at day 32 (p<0.05). Upon re-challenge with A20 lymphoma cells, >80% mice remained free of tumor after 14 days.